

August 12, 2024

To, <b>BSE Limited</b> , 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Ref:</b> Company Scrip Code: 532834	To, Listing Department, <b>National Stock Exchange of India Ltd.</b> , Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 <b>Ref:</b> Symbol: CAMLINFINE    Series: EQ
---	--

**Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”): Unaudited Financial Results for the quarter ended June 30, 2024.**

Dear Sir/Madam,

This has reference to our intimation dated August 5, 2024.

This is to inform you that the Board of Directors, at its meeting held today i.e. Monday, August 12, 2024, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The same are also being uploaded on the Company’s Website (<https://www.camlinfs.com/>). The said Results shall be published in newspapers as per the Listing Regulations.

The Board meeting commenced at 01:00 p.m. (IST) and concluded at 04:30 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

**For Camlin Fine Sciences Limited**

**Rahul Sawale**  
**Company Secretary**  
**& VP - Legal**



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

PART I	PARTICULARS	STANDALONE						CONSOLIDATED		
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		YEAR ENDED
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)	30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)	
1	Revenue from operations	18,191.22	22,032.97	16,111.16	77,326.21	39,385.33	40,169.38	41,960.26	1,61,306.20	
2	Other income	178.01	555.20	601.25	1,888.26	186.76	576.38	636.75	1,555.64	
3	Total income	18,369.23	22,588.17	16,712.41	79,214.47	39,572.09	40,745.76	42,597.01	1,62,861.84	
4	Expenses									
	Cost of materials consumed	13,169.71	10,832.46	10,075.53	42,628.92	21,454.27	13,668.06	24,756.15	74,661.46	
	Purchase of stock in trade	226.12	388.33	90.77	845.85	1,584.26	4,331.16	1,967.13	11,425.87	
	Changes in inventories of finished goods/WIP/stock in trade	(3,196.39)	5,280.30	(3,844.63)	891.99	(1,235.01)	8,163.62	(5,145.24)	5,274.78	
	Employee benefits expense	1,681.32	1,654.18	1,548.09	6,594.84	5,117.79	4,617.01	4,384.85	17,874.77	
	Finance costs	1,361.73	1,387.57	1,204.69	5,432.60	2,337.43	1,616.80	1,022.00	6,030.69	
	Depreciation and amortisation expense	1,269.32	1,278.30	1,179.71	4,939.00	2,011.15	2,004.59	1,878.03	7,860.61	
	Other expenses	5,617.11	6,442.39	5,732.03	23,651.67	10,850.26	10,714.69	12,126.37	44,677.81	
	Total Expenses	20,128.92	27,263.53	15,986.19	84,984.87	42,120.15	45,115.93	40,989.29	1,67,805.79	
5	Profit/ (Loss) before exceptional items and share of profit/ (loss) of associate (3-4)	(1,759.69)	(4,675.36)	726.22	(5,770.40)	(2,348.06)	(4,370.17)	1,607.72	(4,943.95)	
6	Exceptional items (Refer Note 6 & 7)	-	192.84	-	192.84	-	4,980.40	-	4,980.40	
7	Profit/ (Loss) before share of profit/ (loss) of associate (5-6)	(1,759.69)	(4,482.52)	726.22	(5,577.56)	(2,348.06)	(9,350.57)	1,607.72	(9,924.35)	
8	Share of profit/ (loss) of associate	-	-	-	-	-	-	-	-	
9	Profit/ (Loss) before tax (7-8)	(1,759.69)	(4,482.52)	726.22	(5,577.56)	(2,348.06)	(9,350.57)	1,607.72	(9,924.35)	
10	Tax Expenses									
	- Current tax	(378.28)	(62.81)	176.32	-	739.88	651.42	401.56	2,487.23	
	- Deferred tax	(13.40)	(398.09)	(28.14)	(824.32)	377.08	(1,823.48)	4.49	(1,924.07)	
	Total Tax Expenses	(391.68)	(460.90)	148.18	(824.32)	1,116.96	(1,472.06)	406.05	563.16	
11	Profit/ (Loss) for the period (9-10)	(1,368.01)	(4,407.30)	578.04	(5,138.92)	(3,465.02)	(8,178.51)	1,201.67	(10,487.51)	
12	Other comprehensive income									
A	Items that will not be reclassified to profit or loss									
	Remeasurements of defined benefit plans	(15.57)	(2.04)	(10.65)	(8.54)	(15.57)	(2.57)	(10.65)	(9.07)	
	Income tax relating to items that will not be reclassified to profit or loss	5.44	0.71	3.72	2.98	5.44	0.71	3.72	2.98	
B	Items that will be reclassified to profit or loss									
	Exchange differences on translating the financial statements of foreign operations	100.58	(32.51)	211.97	1.70	(650.17)	(69.28)	366.47	1,801.40	
	The effective portion of gain or loss on hedging instruments in a cash flow hedge	(35.15)	11.35	(74.07)	(0.60)	(35.15)	11.35	(74.07)	(0.60)	
	Income tax relating to items that will be reclassified to profit or loss	55.30	(22.49)	130.97	(4.46)	(594.87)	(92.30)	497.44	1,796.41	
13	Other comprehensive income	(1,312.71)	(4,425.79)	799.01	(5,143.38)	(4,059.89)	(8,270.81)	1,699.11	(8,691.10)	
14	Total comprehensive income for the period (11+12)									
	Profit/ (Loss) attributable to:									
	Owners of the Company					(3,395.41)	(7,713.94)	1,555.46	(9,275.34)	
	Non-controlling interests					(69.61)	(464.57)	(353.79)	(1,212.17)	
15	Other comprehensive income attributable to:									
	Owners of the Company					(943.93)	(84.51)	549.35	1,835.36	
	Non-controlling interests					51.06	(7.79)	(51.91)	(38.95)	
16	Total comprehensive income attributable to:									
	Owners of the Company					(4,041.34)	(7,798.45)	2,104.81	(7,439.98)	
	Non-controlling interests					(18.55)	(472.36)	(405.70)	(1,251.12)	
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,674.95	1,674.65	1,674.65	1,674.65	1,674.95	1,674.65	1,673.52	1,674.65	
18	Other Equity									
	Earnings per Share (EPS) (of Re.1/-each) (not annualised)									
	Basic (Rs.)	(0.82)	(2.65)	0.36	(3.09)	(2.03)	(4.64)	0.96	(5.58)	
	Diluted (Rs.)	(0.81)	(2.61)	0.35	(3.05)	(2.01)	(4.58)	0.94	(5.50)	

## Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361





For Camlin Fine Sciences Limited

Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 0107379

**Notes to financial results:**

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 12, 2024. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, 2024 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2024 and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2024	31.03.2024	30.06.2023	31.03.2024	30.06.2024	31.03.2024	30.06.2023	31.03.2024
Exchange gain	15.83	88.33	-	541.51	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Exchange loss	-	-	44.22	-	-	-	598.29	-
Total Exchange gain / (loss)	15.83	88.33	(44.22)	541.51	(Unaudited)	(Audited)	(598.29)	(3,946.68)

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2024	31.03.2024	30.06.2023	31.03.2024	30.06.2024	31.03.2024	30.06.2023	31.03.2024
Exchange gain	-	-	137.57	-	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Exchange loss	20.04	22.15	-	168.78	-	-	616.28	-
Total Exchange gain / (loss)	(20.04)	(22.15)	137.57	(168.78)	(Unaudited)	(Audited)	616.28	(419.58)

- During the quarter ended June 30, 2024, the Company has not allotted any shares under Employees Stock Option Scheme, 2018 (ESOP-2018). During the quarter ended June 30, 2024, the Company has issued and allotted 30,000 equity shares of Rs.1 each at a premium of Rs.62.59 per equity share aggregating to Rs.19,07 lakh under Employees Stock Option Scheme, 2020 (ESOP-2020). No employee stock options have lapsed under ESOP-2018 during the quarter ended June 30, 2024. No employee stock options have lapsed under ESOP-2020 during the quarter ended June 30, 2024.

- Exceptional items in standalone results pertain to impairment of investment in CFS Warglong Flavors (Ningbo) Co., Ltd.(CFSWL) amounting to Rs. 192.84 lakh.

b) Exceptional items in consolidated results include the following impairment provisions pertaining to CFS WL amounting to Rs. 2,700.84 lakh:

- Goodwill Rs. 571.63 lakh
- Inventories & Receivables (net) Rs.549.15 lakh
- Property, plant & Equipments Rs. 1,580.06 lakh

In the opinion of the management of the Company, there are no further indicators of impairment, and therefore, no additional impairment provision is required as of June 30, 2024.

- Exceptional items in consolidated results also include write down of the cost of catalyst and other inventories at CFS Europe S.p.A. amounting to Rs. 2,279.56 lakh.

- On June 11, 2024, wholly owned subsidiary of the company, Dresen Quimica SAPI De CV, Mexico, has acquired entire stake in Vitator Invest NV, Belgium at a consideration of Euro 1. Vitator Invest NV has wholly owned subsidiaries/associate namely Addi-Tech NV (100%); Vitator NV (100%); Vitator China Ltd. (100%); Europe Bio Engineering BV (100%) and Vial Sari (45%) (referred as "Vitator Group"). The consolidated financial statements include the unaudited results of Vitator Group for the period June 11, 2024, to June 30, 2024.

- Revenue and profit / (loss) before tax of CFS Europe considered in consolidated results for the quarter June 30, 2024 is as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2024	31.03.2024	30.06.2023	31.03.2024	30.06.2024	31.03.2024	30.06.2023	31.03.2024
Revenue	3,008.40	4,128.63	11,238.84	22,705.26	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Profit / (Loss) before tax	(1,508.15)	(4,964.25)	(356.73)	(10,756.27)	(Unaudited)	(Audited)	(356.73)	(10,756.27)

No deferred tax has been recognised on the loss for the quarter ended June 2024.

- The Company's operations constitute a single business segment in Speciality Chemicals.



Place: Mumbai  
Date: August 12, 2024

**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361

To  
The Board of Directors  
Camlin Fine Sciences Limited

**LIMITED REVIEW REPORT**

- 1) We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Camlin Fine Sciences Limited ("the Company")** for the quarter ended June 30, 2024 and the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), duly initialled by us for identification.
- 2) This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on August 12, 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3) We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5) Other Matters:


A. With reference to Note 6 to the Statement, pursuant to the decision of the Supreme People's Court of China ("Honorable Court") and based on the impairment testing performed as at March 31, 2024 for the carrying value of its investments in and receivables from its subsidiary company CFS Wanglong Flavors (Ningbo) Co., Ltd. (CFSWL), the Company had done impairment provision of Rs. 192.84 lakh in the standalone audited financial results.

In the opinion of the Management of the Company, there are no further indicators of impairment, and therefore, no additional impairment provision is required as of June 30, 2024.

B. Attention is drawn to the fact that the figures for the quarter ended March 31, 2024, as reported in these financial results are the balancing figures between audited figures in respect of the full financial year ended March 31, 2024, and published unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of third quarter of the said financial year had only been reviewed and not subject to audit.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**  
Chartered Accountants  
Firm Registration No.: 104607W/W/100166



Anil A. Kulkarni

Partner

Membership No.: 047576

UDIN: 24047576BKBJLS6755

Place: Mumbai

Date: August 12, 2024



**KALYANIWALLA  
& MISTRY LLP**

**C H A R T E R E D   A C C O U N T A N T S**

To  
The Board of Directors  
Camlin Fine Sciences Limited

**LIMITED REVIEW REPORT**

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit / loss after tax and total comprehensive income of an associate company of its subsidiary company (refer paragraph 4 below) for the quarter ended June 30, 2024, and the notes thereon ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations"), duly initialled by us for identification.
  - 2) This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by the Parent's Board of Directors, at their respective meetings held on August 12, 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
  - 3) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4) The Statement includes the results of the following entities:

**Incorporated In India**

Sr. No.	Name of the Entity	Relationship
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary

**Incorporated Outside India**

Sr. No.	Name of the Entity	Relationship
i.	CFS North America LLC	Wholly owned subsidiary
ii.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
iii.	Solentus North America Inc	Wholly owned subsidiary
iv.	CFS Europe S.P.A	Wholly owned subsidiary
v.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vi.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
vii.	Nuvel, S.A.C.	Step down subsidiary
viii.	Britec, S.A.	Step down subsidiary
ix.	Inovel, S.A.S	Step down subsidiary
x.	Grinel, S.R.L	Step down subsidiary
xi.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xii.	CFS Pahang Asia Pte. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS De Mexico Blends, S.A.P.I DE CV	Wholly owned subsidiary
xvi.	CFS PP (M) SDN. BHD	Subsidiary
xvii.	Vitafor Invest NV (Belgium) (w.e.f. June 11, 2024)	Step down subsidiary
xviii.	Vitafor NV (Belgium) (w.e.f. June 11, 2024)	Step down subsidiary
xix.	Addi-Tech NV (Belgium) (w.e.f. June 11, 2024)	Step down subsidiary
xx.	Vitafor China (Belgium) (w.e.f. June 11, 2024)	Step down subsidiary
xxi.	Europe Bio Engineering BV (Europe) (w.e.f. June 11, 2024)	Step down subsidiary
xxii.	Vial SARL (w.e.f. June 11, 2024)	Associate Company of a Step down subsidiary



5) Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6(B) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) Other Matters:

A. With reference to Note 6 to the Statement, pursuant to the decision of the Supreme People's Court of China ("Honorable Court") and based on the impairment testing performed as at March 31, 2024 for the carrying value of Goodwill, Property, Plant & Equipment, Inventory and receivables from its subsidiary company CFS Wanglong Flavors (Ningbo) Co., Ltd. (CFSWL), the Company had done impairment provision aggregating to Rs. 2,700.84 lakh in its Consolidated Financial Results comprising of impairment of Goodwill Rs. 571.63 lakh, Inventories and Receivables (net of payables) Rs. 549.15 lakh and Property, Plant and Equipment Rs.1,580.06 lakh in the consolidated audited financial results.

In the opinion of the Management of the Company, there are no further indicators of impairment, and therefore, no additional impairment provision is required as of June 30, 2024.

B. We did not review the interim financial results of 16 subsidiaries, incorporated outside India and 2 subsidiaries incorporated in India, included in the consolidated unaudited financial results, whose financial results reflect the Group's share for the quarter ended June 30, 2024, for the under mentioned items. The interim financial results of a subsidiary incorporated outside India also includes 1 associate company constituting Rs Nil, of the Group's share in the net profit / loss after tax and total comprehensive income for the quarter ended June 30, 2024. These Interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Particulars (before consolidation adjustments)	Quarter Ended June 30, 2024 (Rs. in Lakh)
Total Revenue	27,871.71
Loss after Tax	1,512.37
Total Comprehensive Income	(2,492.56)





**KALYANIWALLA  
& MISTRY LLP**

In respect of these subsidiaries located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries located outside India from accounting principles generally accepted in its respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Parent's Management.

- C. The Statement includes interim financial results of 5 subsidiaries incorporated outside India, which have not been reviewed whose interim financial results reflect the Group's share for the under mentioned items for the quarter ended June 30, 2024.


Particulars (before consolidation adjustments)	Quarter Ended June 30, 2024 (Rs. in Lakh)
Total Revenue	473.45
Loss after Tax	165.78
Total Comprehensive Income	43.83

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such interim financial results. According to the information and explanations given to us by the Parent's Management, these interim financial results are not material to the Group.

- D. Attention is drawn to the fact that the figures for the quarter ended March 31, 2024, as reported in these financial results are the balancing figures between audited figures in respect of the full financial year ended March 31, 2024, and published unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of third quarter of the said financial year, had only been reviewed and not subject to audit.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**  
Chartered Accountants  
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni  
Partner

Membership No.: 047576  
UDIN: 24047576BKBJL.T1437

Place: Mumbai

Date: August 12, 2024





For Camlin Fine Sciences Limited



Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379

Place: Mumbai  
Date: August 12, 2024

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024									
(Rs. in Lakh, except per share data)									
No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	QUARTER ENDED		YEAR ENDED		
		30.06.2024	31.03.2024	30.06.2023	31.03.2024	30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	18,191.22	22,032.97	16,111.16	77,326.21	39,585.33	40,169.38	41,960.26	1,61,306.20
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(1,759.69)	(4,675.36)	726.22	(5,770.40)	(2,348.06)	(4,370.17)	1,607.72	(4,943.95)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(1,759.69)	(4,868.20)	726.22	(5,963.24)	(2,348.06)	(9,350.57)	1,607.72	(9,924.35)
4	Net Profit / (Loss) for the period after tax (after exceptional items)	(1,368.01)	(4,407.30)	578.04	(5,138.92)	(3,465.02)	(8,178.51)	1,201.67	(10,487.51)
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)					(3,395.41)	(7,713.94)	1,555.46	(9,275.34)
6	Total Comprehensive Income for the period	(1,312.71)	(4,429.79)	709.01	(5,143.38)	(4,059.89)	(8,270.81)	1,699.11	(8,691.10)
7	Equity Share Capital	1,674.95	1,674.65	1,673.52	1,674.65	1,674.95	1,674.65	1,673.52	1,674.65
8	Other Equity				69,896.76				84,800.43
9	Earnings per share (of Re 1/-each) (not annualised)	(0.82)	(2.65)	0.36	(3.09)	(2.03)	(4.64)	0.96	(5.58)
	-Basic Rs.	(0.81)	(2.61)	0.35	(3.05)	(2.01)	(4.58)	0.94	(5.50)
	-Diluted Rs.								

1 The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter June 30, 2024 are available on the Company's website at [www.camlinfs.com](http://www.camlinfs.com) and the Stock Exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361